ClinicalTrials.gg
TerminatedNCT05324501MAGIC-G1Updated Feb 10, 2025

A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma

A Phase 1 interventional study of MTX110 and Programmable pump and catheter system in Recurrent Glioblastoma, sponsored by Biodexa Pharmaceuticals. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by Biodexa Pharmaceuticals · Phase 1, Interventional, and Treatment

Why this study was terminated
Strategic decision

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
4
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Enrollment
1,061st of 1,155
4 · median 33
Started
2022
with 56 others
Phase 1
481 of 1,302
70 open now
Registered
1,090th of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 1,061st largest by enrollment of the 1,155 interventional ones that give a count, is one of 57 that started in 2022, is one of 481 in phase 1, and was the 1,090th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

A study designed to assess the safety of MTX110 in patients suffering with recurrent glioblastoma. MTX110 will be administered directly to the site of the tumour via a catheter which is inserted during a surgical procedure at the beginning of the study.

Read the detailed description

A two cohort, ascending dose study of intra-tumoral MTX110 in patients with recurrent glioblastoma. With the aim to assess the safety and also the recommended phase 2 dose of MTX110.

The patient will undergo a surgical procedure to insert a programmable pump and catheter system to allow administration of MTX110 directly to the tumour using Convection Enhanced Delivery (CED).

Cohort A patients will receive one of three potential dose levels of MTX110 as a weekly infusion in order to establish recommended phase 2 dose. This will be based on an accelerated dose titration/3+3 design.

Cohort B patients will follow the 3+3 study design with the starting concentration established in Cohort A. They too will receive MTX110 as a weekly infusion and may undergo catheter repositioning and continued treatment following progression.

03

Conditions studied

  • Recurrent Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recurrent glioblastoma.
  • Patients must be healthy enough to tolerate surgery and general anesthesia.
  • Estimated of greater than 3 months.

Exclusion criteria

Exclusion Criteria:

  • Patients scheduled to undergo or are undergoing re-irradiation for the recurrent tumour.
  • Patients with a history of glioblastoma treatment with carmustine or Gliadel® wafers.
  • Patients who cannot undergo MRI.
  • Patients may not have received chemotherapy or bevacizumab ≤ 4 weeks, or metronomic dosed chemotherapy such as daily etoposide or cyclophosphamide (1 week) prior to starting the study drug.
  • Patients may not have received treatment with tumor treating fields ≤ 1 week prior to starting the study drug.
  • Patients may not be less than 12 weeks from completion of radiation therapy for the primary tumor.
  • Patients with neoplastic lesions in the brainstem, cerebellum, or spinal cord; radiological evidence of active; multifocal disease; extensive subependymal disease (tumor touching subependymal space is allowed); tumor crossing the midline or .
  • Posterior fossa location of the tumor, regardless of its morphology.
  • Prior, unrelated requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin (treatment with tamoxifen or aromatase inhibitors or other hormonal therapy that may be indicated in prevention of prior cancer disease recurrence, are not considered current active treatment).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Cohort A: MTX-110

    Weekly dosing of MTX110 via CED until progression/ unacceptable toxicity.

    Drug: MTX110 · Device: Programmable pump and catheter system

  • Experimental
    Cohort B: MTX-110 with optional catheter repositioning

    Weekly dosing of MTX110 via CED until progression. At progression, optional catheter repositioning may occur, followed by continued weekly dosing of MTX110 until next progression/ unacceptable toxicity.

    Drug: MTX110 · Device: Programmable pump and catheter system

Interventions

  • DrugMTX110

    Soluble panobinostat

  • DeviceProgrammable pump and catheter system

    To allow Convection-Enhanced Delivery (CED)

06

What researchers measure

Primary outcomes

  1. Safety of MTX110 administered by CED

    The frequency and nature of adverse events, serious adverse events and dose limiting toxicities (DLTs).

    Time frame: Through study completion, an expected average of 28 weeks. DLT period 28 days from first dose.

  2. To determine the recommended Phase 2 dose (RP2D) of MTX110

    Time frame: Through study completion, an expected average of 28 weeks

Secondary outcomes

  1. Overall survival

    Time frame: 12 months

  2. Progression-free survival

    Progression based on mRANO criteria

    Time frame: 6 months

  3. Best overall response rate

    Based on mRANO criteria

    Time frame: 6 months

07

Study locations

2 sites
  • Baptist MD Anderson
    Jacksonville, Florida 32207, United States
  • Duke University Hospital
    Durham, North Carolina 27710, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Sep 2024, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2022
First posted
Apr 12, 2022
StartActual
Oct 19, 2022
Primary completionActual
Sep 10, 2024
CompletionActual
Sep 10, 2024
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05324501
Lead sponsor
Biodexa Pharmaceuticals
Responsible party
Sponsor
First posted
Apr 12, 2022
Start date
Oct 19, 2022
Primary completion
Sep 10, 2024
Completion
Sep 10, 2024
Last update
Feb 10, 2025

Study contacts

Gary Shangold
study director · Biodexa Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panobinostat Nanoparticle Formulation MTX110

Start the discussion